Clinical trial
Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular…
NCT03306277 · Novartis Gene Therapies, Industry · Completed
Key facts
| NCT number | NCT03306277 |
|---|---|
| Title | Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1 |
| Official title | Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion |
| Acronym | STR1VE |
| Lead sponsor | Novartis Gene Therapies, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | SMA - Spinal Muscular Atrophy, Gene Therapy |
| Intervention type | Biological |
| Interventions | Onasemnogene Abeparvovec-xioi |
| Enrollment | 22 |
| Start date | Oct 24, 2017 |
| Primary completion | Nov 12, 2019 |
| Completion | Nov 12, 2019 |
| First posted | Oct 11, 2017 |
| Last update posted | Jan 26, 2026 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: